Cancer Research Horizons is Cancer Research UK’s innovation engine dedicated to transforming lab discoveries into effective cancer treatments and diagnostics. Specializing in early-stage investments, it supports biotech and pharmaceutical ventures such as NK:IO. To date, it has helped create over 60 spin-out companies and introduced 11 new cancer drugs to the market. As a key player in global cancer research treatment licensing, it gains exclusive access to over £300 million in cutting-edge research. Its mission is to bridge the gap between research and the market, ensuring all funds are reinvested into developing future cancer breakthroughs to conquer cancer.
